GALENICA N/ CH0360674466 /
2024-04-25 11:59:54 AM | Chg. -0.20 | Volume | Bid12:09:13 PM | Ask12:09:13 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
70.85CHF | -0.28% | 8,087 Turnover: 570,994.28 |
70.70Bid Size: 233 | 70.85Ask Size: 470 | 3.53 bill.CHF | 3.12% | 12.33 |
GlobeNewswire
2023-09-18
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
GlobeNewswire
2021-11-17
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
GlobeNewswire
2021-08-19
Biofrontera reports financial results for the six months ended June 30, 2021
GlobeNewswire
2020-12-07
Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz®...
GlobeNewswire
2019-07-11
Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer...
GlobeNewswire
2019-06-18
Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance O...
GlobeNewswire
2018-05-23
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensin...
GlobeNewswire
2018-05-23
VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE...
GlobeNewswire
2018-05-08
Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa®...
GlobeNewswire
2018-04-16
Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders
GlobeNewswire
2018-04-11
Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at t...
GlobeNewswire
2018-03-27
VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN